

Clinical evaluation
[Rx1]
Six months
R
PR
NR
Clinical Outcome
Explant evaluation
Tumor
[P0]
[Rx1, Rx2, RxN]
One week
R
PR
NR
Explant Outcome
In vivo evaluation
Passage 1
[P1]
Passage 2
[P2]
[Rx1, Rx2, RxN]
4-6 months
R
PR
NR
Human Tumor Xenograft Outcome
Demonstration of equivalence of P0, P1, P2 by efficacy and molecular profiling experiments.

Figure 1



A T0
B T48
C T72
AL- Autologous serum derived ligands
D T48
E T72

Figure 2




Figure 3A




Figure 3B



a
% Cell viability
100
80
60
40
20
0
**
Control
Autologous Serum
b
T0hr Control
T72hrs Control
T72hrs Autologous serum
H&E
Ki67
c
% Cell viability
150
120
90
60
30
0
*
*
T0-Control
T72-Control
Gelatin
Collagen
ECM
Matrigel
d
H&E
Ki67
T0hr Control
T72hrs Matrigel
T72hrs ECM
e
No. Ki67 cells/section
250
200
150
100
50
0
T0-Control
T72-Control
Gelatin
Collagen
Matrigel
ECM
f
No. Ki67 cells/section
250
200
150
100
50
0
T0-Control
T72-Control
2% Serum
ECM
Serum+ECM
g
T0-Control
T72-Control
Ki67
Serum
ECM
Ki67
ECM+Serum
Ki67

Figure 4



a
Percent of ECM composition
25
20
15
10
5
0
Cytokeratin type-2
Cytokeratin type-1
Histone
Novel protein
Collagen a-1
Collagen a-2
Collagen a-3
Hemoglobin
Actin
Beta Globin
Myosin
Fibronectin
Dermcidin
Vimentin
b
% Cell viability
120
100
80
60
40
20
0
T0
0ug
1ug
10ug
100ug
72hrs
*
*
c
Incubated for 72hrs with ECM(ug)
T0
0
1
10
100
H&E
Ki-6

Figure 5



a
Ki67
p-EGFR
H&E
T 0 hr Control
T 72hrs Control
T 72hrs ECM
T 72hrs Collagen
T 72hrs Gelatin
T 72hrs Matrigel
b
Ki67 +ve cells/sections
250
200
150
100
50
0
Base line T0
Uncoated
ECM
Collagen
Gelatin
Matrigel
Culture for 72hrs
c
Ki67 +ve cells/sections
200
150
100
50
0
Control
ECM

Figure 6




Figure 7




Figure 8




Figure 9




Figure 10



CaPan GNF
NR
R
HNSC GNF
NR
R
CRC Cet
NR
R
HNSCC Cet
NR
R
HNSCC TPF
NR
R
-4
-2
0
2
4
6
No Response
Response

Figure 11




Figure 12







Figure 13




E F



G




H




I


Figure 13




J



K




L




M


Figure 13




N



O




P




Q

Figure 13


M-Score
75
50
25
0
Rx1 Rx2 Rx3 Rx4 Rx5 Rx6 Rx7 Rx8

R


M-Score
75
50
25
0
Rx1 Rx2 Rx3 Rx4 Rx5 Rx6

S

Figure 13